The purpose of this Funding Opportunity Announcement (FOA) is to support the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.
Projects that are exploratory and novel, break new ground or extend previous discoveries toward new directions or applications, are better suited for the companion FOA soliciting R21 exploratory/developmental projects, PAR-19-346.
Applications that propose long-term projects and projects designed to increase knowledge in a well-established area are better suited for PAR-18-712, Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R01 Clinical Trial Not Allowed).
Deadlines:
PAR-19-347 Expiration Date: New Date March 23, 2021 per issuance of NOT-AI-21-034. (Original Expiration Date: July 17, 2022 )
The total project period may not exceed two years.
